Skip to main content
Journal cover image

Molecular analysis-based treatment strategies for the management of non-small cell lung cancer.

Publication ,  Journal Article
West, H; Lilenbaum, R; Harpole, D; Wozniak, A; Sequist, L
Published in: J Thorac Oncol
September 2009

Even with the introduction of targeted agents and the establishment of multiple lines of therapy, the median survival for patients with advanced non-small cell lung cancer (NSCLC) does not considerably extend beyond 1 year. Emerging research suggests that clinical characteristics alone are insufficient for selecting patients for therapies that may confer significant survival benefit. The discovery of predictive and prognostic molecular markers such as gene mutations in EGFR and KRAS as well as high tumor expression levels of DNA repair pathway components ribonucleotide reductase subunit 1 and excision repair cross-complementing group 1 has sparked an interest in the development of individualized therapy as a strategy for increasing survival in patients with NSCLC. Techniques to analyze molecular biomarkers, such as immunohistochemistry, fluorescence in situ hybridization, polymerase chain reaction, and, more recently, gene microarray techniques, are being investigated for their potential to accurately predict an individual patient's response to therapy. Many prospective trials are still needed to clarify and confirm the utility of molecular biomarkers for guiding treatment selection, and continued participation in clinical trials is critical for the development of tools to provide customized treatment plans for patients with NSCLC.

Duke Scholars

Published In

J Thorac Oncol

DOI

EISSN

1556-1380

Publication Date

September 2009

Volume

4

Issue

9 Suppl 2

Start / End Page

S1029 / S1039

Location

United States

Related Subject Headings

  • Prognosis
  • Oncology & Carcinogenesis
  • Neoplasm Proteins
  • Lung Neoplasms
  • Humans
  • Carcinoma, Non-Small-Cell Lung
  • Biomarkers, Tumor
  • Antineoplastic Agents
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
West, H., Lilenbaum, R., Harpole, D., Wozniak, A., & Sequist, L. (2009). Molecular analysis-based treatment strategies for the management of non-small cell lung cancer. J Thorac Oncol, 4(9 Suppl 2), S1029–S1039. https://doi.org/10.1097/JTO.0b013e3181b27170
West, Howard, Rogerio Lilenbaum, David Harpole, Antoinette Wozniak, and Lecia Sequist. “Molecular analysis-based treatment strategies for the management of non-small cell lung cancer.J Thorac Oncol 4, no. 9 Suppl 2 (September 2009): S1029–39. https://doi.org/10.1097/JTO.0b013e3181b27170.
West H, Lilenbaum R, Harpole D, Wozniak A, Sequist L. Molecular analysis-based treatment strategies for the management of non-small cell lung cancer. J Thorac Oncol. 2009 Sep;4(9 Suppl 2):S1029–39.
West, Howard, et al. “Molecular analysis-based treatment strategies for the management of non-small cell lung cancer.J Thorac Oncol, vol. 4, no. 9 Suppl 2, Sept. 2009, pp. S1029–39. Pubmed, doi:10.1097/JTO.0b013e3181b27170.
West H, Lilenbaum R, Harpole D, Wozniak A, Sequist L. Molecular analysis-based treatment strategies for the management of non-small cell lung cancer. J Thorac Oncol. 2009 Sep;4(9 Suppl 2):S1029–S1039.
Journal cover image

Published In

J Thorac Oncol

DOI

EISSN

1556-1380

Publication Date

September 2009

Volume

4

Issue

9 Suppl 2

Start / End Page

S1029 / S1039

Location

United States

Related Subject Headings

  • Prognosis
  • Oncology & Carcinogenesis
  • Neoplasm Proteins
  • Lung Neoplasms
  • Humans
  • Carcinoma, Non-Small-Cell Lung
  • Biomarkers, Tumor
  • Antineoplastic Agents
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences